Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 infections fell significantly – by 65% - after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.

Vaccine being administered in to the arm of a patient

Data from the COVID-19 Infection Survey, a partnership between the University of Oxford, the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC), is the first to show the impact of vaccination on antibody responses and new infections in a large group of adults from the general population aged 16 years and older.

Two studies, released today as pre-prints, focused on the protection from infection provided by COVID-19 vaccines. Researchers analysed 1,610,562 test results from nose and throat swabs taken from 373,402 study participants between 1 December 2020 and 3 April 2021. 21 days after a single dose of either Oxford-AstraZeneca or Pfizer-BioNTech vaccines (with no second dose), the rates of all new COVID-19 infections had dropped by 65%, symptomatic infections by 72% and infections without reported symptoms by 57%.

Reductions in infections and symptomatic infections were even greater after a second dose (70% and 90% respectively), and were similar to effects in those who had previously been infected with COVID-19 naturally. Vaccines were effective against variants compatible with the Kent strain (B.1.1.7). Benefits from vaccines in reducing new infections were similar in older individuals over 75 years and under 75 years, and in those reporting long-term health conditions and not reporting them.

Read the full news article on the University of Oxford website

Similar stories

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

New study shows higher rate of fractures in people with intellectual disability

In the most comprehensive study of its kind, researchers at the University of Oxford and Oxford Health NHS Foundation Trust found a substantially higher rate of fractures in people with intellectual disability compared with people of the same age and gender without an intellectual disability.

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.